Загрузка...
Development and characterization of an anti-rituximab monoclonal antibody panel
During the development of monoclonal antibodies (mAbs) and other therapeutic proteins, immunogenicity, in particular the induction of anti-drug antibodies (ADAs), is an important concern, and thus immunogenicity assessment is a requirement for their approval. Establishment of appropriate methods for...
Сохранить в:
| Опубликовано в: : | MAbs |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Taylor & Francis
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5916554/ https://ncbi.nlm.nih.gov/pubmed/29309213 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2018.1424610 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|